Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges.
HER2-positive breast cancer
antibody-drug conjugates
mechanisms of resistance
trastuzumab deruxtecan
trastuzumab emtansine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Feb 2023
10 Feb 2023
Historique:
received:
12
01
2023
revised:
02
02
2023
accepted:
06
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
The treatment of HER2-positive metastatic breast cancer (mBC) with Trastuzumab emtansine (T-DM1) and Trastuzumab deruxtecan (T-DXd), two antibody-drug conjugates (ADCs) targeting HER2, is burdened by progression of disease related to the acquisition of mechanisms of resistance. Resistance to T-DM1 is caused by the decrease of HER2 expression, the alteration of intracellular trafficking, the impairment of lysosome functions, the drug expulsion through efflux pumps and the activation of alternative signal pathways. Instead, the decrease of HER2 expression and
Identifiants
pubmed: 36831473
pii: cancers15041130
doi: 10.3390/cancers15041130
pmc: PMC9954056
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Rev Mol Cell Biol. 2007 Aug;8(8):603-12
pubmed: 17609668
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
pubmed: 17440164
Cancer Cell. 2016 Jan 11;29(1):117-29
pubmed: 26766593
Cancer Discov. 2021 Oct;11(10):2436-2445
pubmed: 34404686
Br J Cancer. 2022 Oct;127(7):1214-1225
pubmed: 35794238
Health Phys. 2003 Jul;85(1):31-5
pubmed: 12852468
Nat Commun. 2018 Dec 3;9(1):5137
pubmed: 30510281
CA Cancer J Clin. 2020 Sep;70(5):355-374
pubmed: 32813307
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Mol Cancer Ther. 2020 Sep;19(9):1833-1843
pubmed: 32669315
Mol Cancer Ther. 2018 Jul;17(7):1494-1503
pubmed: 29703841
Cancers (Basel). 2021 Dec 29;14(1):
pubmed: 35008318
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
Lancet. 2023 Jan 14;401(10371):105-117
pubmed: 36495879
Clin Cancer Res. 2016 Oct 1;22(19):4859-4869
pubmed: 27697991
J Pathol. 2005 Jan;205(2):275-92
pubmed: 15641020
J Clin Oncol. 2019 Oct 10;37(29):2601-2609
pubmed: 31442103
PLoS One. 2013 Jun 26;8(6):e66961
pubmed: 23840564
Mol Cancer Ther. 2015 Apr;14(4):952-63
pubmed: 25646013
Sci Rep. 2021 Aug 19;11(1):16891
pubmed: 34413454
Cancer Biol Ther. 2008 Oct;7(10):1630-40
pubmed: 18769124
Breast Cancer Res. 2017 Oct 3;19(1):110
pubmed: 28974266
EMBO J. 2009 Sep 2;28(17):2601-15
pubmed: 19629035
Nat Rev Immunol. 2017 Apr;17(4):262-275
pubmed: 28287107
Sci Transl Med. 2015 Nov 25;7(315):315ra188
pubmed: 26606967
Mol Cancer Res. 2020 Apr;18(4):644-656
pubmed: 31900313
Nat Rev Drug Discov. 2017 May;16(5):315-337
pubmed: 28303026
Mol Cancer Ther. 2018 Jan;17(1):243-253
pubmed: 29054985
Mol Cancer Ther. 2018 Jul;17(7):1441-1453
pubmed: 29695635
Cancers (Basel). 2021 Mar 01;13(5):
pubmed: 33804398
Nat Rev Clin Oncol. 2010 Jun;7(6):309-17
pubmed: 20368727
Clin Exp Immunol. 2019 Jun;196(3):318-327
pubmed: 30756386
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
BioDrugs. 2021 Mar;35(2):159-174
pubmed: 33666903
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Adv Cancer Res. 2010;108:73-112
pubmed: 21034966
J Hematol Oncol. 2021 Jan 28;14(1):20
pubmed: 33509252
Cell Death Discov. 2022 Dec 3;8(1):478
pubmed: 36463209
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
Cancer Discov. 2020 May;10(5):674-687
pubmed: 32213539
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059433
CA Cancer J Clin. 2022 Mar;72(2):165-182
pubmed: 34767258
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-12
pubmed: 33793316
J Clin Oncol. 2010 Mar 10;28(8):1301-7
pubmed: 20142587
Lancet Oncol. 2017 Jun;18(6):743-754
pubmed: 28526538
CA Cancer J Clin. 2022 Nov;72(6):524-541
pubmed: 36190501
F1000Res. 2019 Sep 30;8:
pubmed: 31602296
Cancer Res. 2011 Mar 1;71(5):1515-9
pubmed: 21343397
Nat Commun. 2022 May 9;13(1):2526
pubmed: 35534471
Pharm Res. 2015 Nov;32(11):3526-40
pubmed: 25759187
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Eur J Cancer. 2007 Nov;43(16):2423-33
pubmed: 17911008
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Mol Biol Cell. 2004 Dec;15(12):5268-82
pubmed: 15385631
Clin Breast Cancer. 2021 Feb;21(1):80-91.e7
pubmed: 33183970
Front Mol Biosci. 2022 Mar 15;9:834651
pubmed: 35372498
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
Clin Cancer Res. 2020 Feb 1;26(3):608-622
pubmed: 31591187
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207890
Mol Cancer Ther. 2014 Nov;13(11):2618-29
pubmed: 25189543
Nat Commun. 2020 Jan 20;11(1):385
pubmed: 31959756
Breast Cancer Res. 2011 Apr 21;13(2):R46
pubmed: 21510863